Geode Capital Management LLC Lowers Holdings in Qiagen (NYSE:QGEN)

Geode Capital Management LLC lowered its position in Qiagen (NYSE:QGEN - Free Report) by 3.8% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,055,671 shares of the company's stock after selling 42,127 shares during the period. Geode Capital Management LLC owned about 0.46% of Qiagen worth $48,107,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. Raymond James Trust N.A. bought a new position in shares of Qiagen during the 2nd quarter worth approximately $204,000. Bank of New York Mellon Corp boosted its position in Qiagen by 6.3% in the second quarter. Bank of New York Mellon Corp now owns 972,131 shares of the company's stock worth $39,945,000 after purchasing an additional 57,444 shares during the last quarter. Panagora Asset Management Inc. increased its position in shares of Qiagen by 23.3% during the 2nd quarter. Panagora Asset Management Inc. now owns 18,483 shares of the company's stock valued at $759,000 after purchasing an additional 3,497 shares during the last quarter. Banque Cantonale Vaudoise bought a new stake in shares of Qiagen during the 2nd quarter worth $314,000. Finally, Van ECK Associates Corp boosted its holdings in shares of Qiagen by 4.7% in the 2nd quarter. Van ECK Associates Corp now owns 218,431 shares of the company's stock worth $8,975,000 after buying an additional 9,844 shares during the last quarter. 70.00% of the stock is owned by institutional investors.

Analysts Set New Price Targets

QGEN has been the topic of several research reports. HSBC lowered shares of Qiagen from a "buy" rating to a "hold" rating and set a $49.00 price objective on the stock. in a research report on Thursday, October 17th. Jefferies Financial Group reiterated a "buy" rating and issued a $54.00 price objective (up previously from $42.00) on shares of Qiagen in a research note on Tuesday, December 10th. Finally, Hsbc Global Res raised Qiagen to a "hold" rating in a research report on Thursday, October 17th. Three research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $51.88.

Qiagen Stock Performance

Shares of Qiagen stock traded up $0.24 during trading hours on Tuesday, reaching $45.06. The company had a trading volume of 173,389 shares, compared to its average volume of 1,133,198. The firm has a market cap of $10.28 billion, a PE ratio of 115.54, a price-to-earnings-growth ratio of 3.52 and a beta of 0.35. Qiagen has a one year low of $39.03 and a one year high of $47.44. The company has a debt-to-equity ratio of 0.39, a current ratio of 2.17 and a quick ratio of 1.89. The business has a fifty day simple moving average of $43.36 and a 200 day simple moving average of $43.76.

Qiagen Profile

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.